Egalet Corporation (NASDAQ:EGLT) Files An 8-K Entry into a Material Definitive Agreement

ME Staff 8-k
-
0

Egalet Corporation (NASDAQ:EGLT) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement

Exchange Agreement

On December20, 2017, Egalet Corporation (the “Company”) entered into exchange agreements (the “Exchange Agreements”) with certain holders (the “Holders”) of the Company’s 5.50% convertible senior notes due 2020 (the “5.50% Notes”) to which the Holders have agreed to exchange, in the aggregate, approximately $36.4 million of outstanding principal amount of the 5.50% Notes for, in the aggregate, (i)approximately $23.9 million of the Company’s new 6.50% convertible senior notes due 2024 (the “New Notes”), (ii)a warrant exercisable for 3.5 million shares of the Company’s common stock and (iii)payments, in cash, of all accrued but unpaid interest as of the closing on the 5.50% Notes exchanged in the transaction (the “Exchange”). The Exchange Agreements include the terms and conditions of the exchange of the 5.50% Notes and issuance and sale of the New Notes, customary representations and warranties, and other terms and conditions customary in agreements of this type. The Exchange Agreements also provide that, for a period of nine months, the Company will not enter into additional exchange transactions with the other holders of the 5.50% Notes on terms more favorable to the noteholders (relative to the New Notes) without the written consent of the holders of a majority of the outstanding principal amount of the New Notes. The Exchange is expected to close on Friday, December22, 2017, subject to customary closing conditions.

The New Notes will pay interest semiannually in arrears on January1 and July1 of each year commencing July1, 2018 at a rate of 6.50% per year, which rate is subject to adjustment in accordance with the terms of the indenture that will govern the New Notes (the “Indenture”) and as described below. The New Notes will mature on December31, 2024, unless earlier repurchased, redeemed or converted in accordance with the terms of the Indenture prior to such date. Subject to certain conditions, on or after January1, 2021, the Company may redeem for cash all or a part of the New Notes. The New Notes will be convertible at any time until the close of business on the business day immediately preceding the maturity date. Upon conversion and subject to certain conditions, holders of the New Notes will receive shares of the Company’s common stock at an initial conversion rate of 749.6252 shares of common stock per $1,000 principal amount of New Notes, which is equivalent to an initial conversion price of approximately $1.33 per share, and is subject to adjustment under the terms of the New Notes. This represents a premium of approximately 15% over the last reported sale price of $1.16 per share of Egalet’s common stock on The NASDAQ Global Market on December19, 2017. Similar to the 5.50% Notes, the New Notes will provide for an interest make-whole payment in connection with conversions that occur prior to July1, 2021.

In addition, the indenture that will govern the New Notes will require the Company to use its reasonable best efforts to (i)seek stockholder approval of an amendment to the Company’s Third Amended& Restated Certificate of Incorporation, as amended, in order to increase the amount of authorized shares available for issuance thereunder, and (ii)if and when such approval is obtained, to reserve from such amount the number of shares that may be issued in respect of the New Notes and any other securities issued in connection with the Exchange. In the Exchange Agreements, the Holders have granted a proxy to the Company authorizing the Company to vote any shares of common stock held by such Holder in favor of such amendment at any applicable meeting of the Company’s stockholders. If the Company is unable to obtain stockholder approval on or prior to July1, 2018, the interest rate of the New Notes will increase to 10.0% unless and until such stockholder approval is obtained.

The foregoing summary is qualified in its entirety by reference to the forms of Exchange Agreement, which are attached hereto as Exhibits 10.1 and 10.2 and incorporated herein by reference.

Item 8.01 — Other Events

On December20, 2017, the Company issued a press release announcing that the Company had entered into the Exchange Agreements. A copy of the press release is attached hereto as Exhibit99.1 and incorporated herein by reference.

Additional Information

This report on Form8-K is neither an offer to sell, nor a solicitation of an offer to buy, any securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The

securities described herein have not been and will not be registered under the Securities Act, or any state securities laws, and unless so registered, may not be offered or sold in the United States except to an exemption from the registration requirements of the Securities Act, and applicable state securities laws.

Forward-Looking Statements

Except for historical information, all other information in this report on Form8-Kconsists of forward-looking statements. Statements that are not historical facts, including statements about our beliefs and expectations are forward-looking statements. Statements containing the words “may”, “could”, “would”, “should”, “believe”, “expect”, “anticipate”, “plan”, “estimate”, “target”, “project”, “intend” and similar expressions constitute forward-looking statements. These forward-looking statements involve a number of risks, uncertainties and other factors, including the possible completion of the Exchange, the prospective impact of the Exchange on the Company’s common stock, other indebtedness and financial condition, the Company’s ability to satisfy the conditions contained in the Exchange Agreements and other factors discussed in our public filings, including the risk factors included in the Company’s most recent Annual Report on Form10-K (as supplemented by the Company’s Quarterly Reports on Form10-Q),which may cause the actual results to be materially different from those expressed or implied in the forward-looking statements. There can be no assurance that the Exchange will be completed as described herein or at all. Other important factors are discussed under the caption “Forward-Looking Statements” in the most recent Annual Report on Form10-Kand in subsequent filings made prior to or after the date hereof. The Company does not intend to review or revise any particular forward-looking statement in light of future events.

Item 9.01 — Financial Statements and Exhibits

(d)Exhibits


Egalet Corp Exhibit
EX-10.1 2 a17-28729_1ex10d1.htm EX-10.1 Exhibit 10.1   EXECUTION VERSION   EXCHANGE AGREEMENT                                                          (the “Undersigned”),…
To view the full exhibit click here

About Egalet Corporation (NASDAQ:EGLT)

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.